Adult Vaccine Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis

Adult Vaccine Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis

Adult Vaccine Market is expected to reach US$ 26.7 Billion by 2027. Adult vaccination is one of the most cost-effective strategies available in public health today. Each year, vaccine-preventable diseases kill thousands of adults across the world. Adult immunization includes the administration of licensed vaccines provided to patients aged 18 years and older for medical indications. However, vaccines are used to prevent diseases and improve the body's immunity. A vaccine is a biological practice, contains an agent that resembles a disease-causing microorganism, and is made from weakened and killed forms of microorganisms.

Recently, the increasing prevalence of diseases and novel vaccine technologies has been significant drivers for the global adult vaccines market. In addition, increased research in vaccine technologies and increasing government support also support the growth of the global adult vaccines market. In 2021, by Pfizer Vaccine Product Pipeline, XTANDI™ (enzalutamide) for adult men with metastatic hormone-sensitive prostate cancer (mHSPC, also know n as metastatic castration-sensitive prostate cancer or mCSPC) (E.U.)

How COVID-19 has Benefited the Adult Vaccine Market

Pandemic COVID-19 had mixed impact on vaccines industry. Some of the vaccines vaccination rates have declined. On the contrary few vaccines vaccination rates have jumped such as flu vaccines. The launches of COVID-19 vaccines have made a huge impact on the overall growth of vaccines industry. The vaccines industry has registered a growth of Billion of USD in the year 2021. According to Renub Research report, Global Adult Vaccine Industry is projected to grow with a CAGR of 6% from 2021-2027.

Adult Vaccine Market Size was US$ 18.8 Billion in 2021

The global adult vaccines disease segment includes Influenza, Cervical Cancer (HPV), Zoster (Shingles), MMR (Measles, Mumps, and Rubella Vaccine), Pneumococcal, Meningococcal, Hepatitis, TdaP, Travel and Miscellaneous, Varicella. Pneumonia is a disorder that drives lung contamination in one or both the lungs induced by viruses, bacteria organisms, or fungi; bacterial pneumonia is the most familiar in adults. However, adults are more prone to pneumococcal contaminations and even death. Pneumonia vaccines are primarily given to adults; in general, single-dose vaccines given to adults. These vaccines help provide immunizations against 13 types of pneumococcal bacteria that cause lung infection.

The viral infection due to flu in the respiratory system is called influenza. The influenza virus traverses through respiratory droplets, and it is contagious. It also spreads from one person to another while physical contact and talking, particularly in adults. Healthcare organizations all over the world, like the (CDC) Centers for Disease Control and Prevention, have suggested vaccines like baloxavir marboxil (Xofluza) for the treatment of influenza have recommended certain influenza vaccines such as baloxavir marboxil (Xofluza) to treat the symptoms in adults.

According to CDC 2019-2018, Vaccinated by disease:

• 45% of adults received the vaccine for Influenza
• 69% of adults receive a pneumococcal vaccination
• 49% of adolescents aged 13-17 received the HPV vaccination

Key Industry Players:

The key players operating in the vaccine industry include GlaxoSmithKline, plc.’s Vaccines Sales, Merck & Co. Vaccines Sales, Sanofi Pasteur’s Vaccines Sales, Pfizer, Inc.’s Vaccines Sales, Thoracic Aortic Aneurysm (TAA) CSL Limited sales. In 2021 – GlaxoSmithKline plc announced that they have introduce a (BLA) Biologics License Application to the U.S. FDA for their investigational vaccine PRIORIX and desires approval to use it against measles, mumps, and rubella (MMR) in the U.S. region. The vaccine was first registered in Germany and is presently licensed in over 100 countries globally.

Renub Research latest report “Adult Vaccines Market Disease wise ( Influenza, Cervical Cancer (HPV), Zoster (Shingles), MMR (Measles, Mumps, and Rubella Vaccine), Pneumococcal, Meningococcal, Hepatitis, TdaP, Travel and Miscellaneous, Varicella) Numbers of Vaccinated Adults (Influenza, Cervical Cancer (HPV), Zoster (Shingles), MMR (Measles, Mumps, and Rubella Vaccine), Pneumococcal, Meningococcal, Hepatitis, TdaP, Varicella) by company analysis (GlaxoSmithKline, plc.’s Vaccines Sales, Merck & Co. Vaccines Sales, Sanofi Pasteur’s Vaccines Sales, Pfizer, Inc.’s Vaccines Sales, Thoracic Aortic Aneurysm (TAA) CSL Limited sales)” provides a detailed analysis of Adult Vaccines Industry

Disease wise – Adult Vaccine Market has been covered from 11 viewpoints

1. Coronavirus (COVID-19)
2. Influenza
3. Cervical Cancer (HPV)
4. Zoster (Shingles)
5. MMR (Measles, Mumps, and Rubella Vaccine)
6. Pneumococcal
7. Meningococcal
8. Hepatitis
9. TdaP
10. Travel and Miscellaneous
11. Varicella

Disease wise – Numbers of Vaccinated Adults has been covered from 10 viewpoints

1. Coronavirus (COVID-19)
2. Influenza
3. Cervical Cancer (HPV)
4. Zoster (Shingles)
5. MMR
6. Pneumococcal
7. Meningococcal
8. Hepatitis
9. TdaP
10. Varicella

Company Insights

• Overviews
• Recent Developments
• Revenues

Company Analysis:

1. GlaxoSmithKline, plc.’s
2. Merck & Co.
3. Sanofi Pasteur’s
4. Pfizer, Inc.’s
5. CSL Limited